Teijin Limited,Japan Tissue Engineering Co., Ltd.(J-TEC),Mitsui Fudosan Co., Ltd.and theNational Cancer Center(NCC)jointly announced today thatthey willestablish a regenerative medicine platform inKashiwanoha Smart City,a life sciencebusiness park in Kashiwa-shi, Chiba Prefecture, Japan. The platform supports the development of innovative treatments for diseases with unmet needs such as cancer. It serves a one-stop system supporting research and development, business plan formulation, and commercial production of regenerative medicine products.In particular, the four partners aim to accelerate the commercialization of regenerative medicine and innovative treatments for cancer.As part of the plan, the partners already have begun to support seed holders.
Looking at the four partners: NCC provides cutting-edge cancer treatments and produces drug discovery seeds; J-TEC has extensive experience in product development, manufacturing and marketing as a pioneer of regenerative medicines; Teijin boasts expertise in drug research, development and marketing; and Mitsui Fudosan builds spaces and communities for innovation in life sciences. Their envisioned platform, taking advantage of the physical and functional proximity of the four parties, is expected to quickly and efficiently provide solutions for manufacturing and clinical development, business planning and commercial production. The contract development and manufacturing organization (CDMO) served by Teijin and J-TEC will be located in Mitsui Link-Lab Kashiwanoha 1 operated by Mitsui Fudosan, and is adjacent to the NCC Hospital East and NCC Exploratory Oncology Research & Clinical Trial Center.
The platform will also support projects of other organizations that have seeds. NCC will provide professional consulting and collaboration with seeds holders and investigator-initiated clinical trials. Teijin and J-TEC offer practical consulting and support for contracted development and manufacturing. Mitsui Fudosan will be responsible for venue operation and providing support for individual initiatives.
In preparation to start up the CDMO facility scheduled to open in January 2024, the platform will promote the development of regenerative medicines among academic institutions,start-up companies, pharmaceutical companies and others. It also will solicit research and development and clinical collaborations with medical institutions as well as key opinion leaders (KOL) and business enterprises in the fields of cancer and regenerative medicine.
With this agreement, the four parties will strive to stimulate demand and build up their platform, aiming eventually at establishing a structure capable of supporting about 10 projects annually with the purpose of bringing regenerative medicines to market. Teijin, in collaboration with J-TEC, will invest a substantial portion of its more than JPY 3 billion CDMO-related investment budget into the project, mainly for facilities and human resource training in Mitsui Link-Lab Kashiwanoha 1 over the next two to three years, thereby helping to establish a CDMO facility mainly for supporting the development of manufacturing methods as well as actual manufacturing. Ultimately, the four parties expect to contribute to global medical care by providing new options for patients waiting for innovative treatments.
According to the NCC, some one million people are diagnosed with cancer each year in Japan. Development of innovative treatments using regenerative medicines, including genetically modified immune cell therapy, also known as chimeric antigen receptor (CAR-T) cell therapy, has been ongoing worldwide in recent years. In addition, research and development of promising treatments and their seeds are under way. Meanwhile, the practical application of regenerative medicine requires specialized knowledge and practical experience regarding matters such as pharmaceutical approval and quality control. A wide range of commercialization knowhow also is required. As a result, many academic institutions and start-up companies are unable to commercialize their research and development independently. Teijin, J-TEC, Mitsui Fudosan and NCC, based on their clear understanding of such needs, have now agreed to establish a regenerative medicine platform to provide academic institutions with professional expertise and commercialization knowhow on a collaborative basis.
Kashiwa-no-ha Smart City, which is served by Kashiwa-no-ha Campus Station about 30 minutes by express train from central Tokyo, is an area with accumulation of Japans leading academic and medical institutions for some of Japan's leading academia and medical facilities. In addition to Mitsui Garden Hotel Kashiwa-no-ha Parkside, which supports cancer patients, the smart city has become a lively community of offices and commercial facilities.Mitsui Link Lab Kashiwanoha 1, located at6-6-2 Kashiwanoha, Kashiwa-shi, ChibaPrefecture, comprises about11,000m2of total floor space and offers rentalspace ofabout 8,000 m2.
About the Teijin Group
Teijin (TSE: 3401) is a technology-driven global group offering advanced solutions in the fields of environmental value; safety, security and disaster mitigation; and demographic change and increased health consciousness. Originally established as Japan's first rayon manufacturer in 1918, Teijin has evolved into a unique enterprise encompassing three core business domains: high-performance materials including aramid, carbon fibers and composites, and also resin and plastic processing, films, polyester fibers and products converting; healthcare including pharmaceuticals and home healthcare equipment for bone/joint, respiratory and cardiovascular/metabolic diseases, nursing care and pre-symptomatic healthcare; and IT including B2B solutions for medical, corporate and public systems as well as packaged software and B2C online services for digital entertainment. Deeply committed to its stakeholders, as expressed in the brand statement Human Chemistry, Human Solutions, Teijin aims to be a company that supports the society of the future. The group comprises some 170 companies and employs some 20,000 people across 20 countries worldwide. Teijin posted consolidated sales of JPY 926.1 billion (USD 7.2 billion) and total assets of JPY 1,207.6 billion (USD 9.4 billion) in the fiscal year that ended on March 31, 2022.
Please visitwww.teijin.com
About J-TEC
J-TEC (TSE: 7774) is a maker of regenerative medical products whose corporate vision is creating a future for regenerative medicine, and has been a member of the Teijin Group since March 2021. As Japans top runner in regenerative medicine, J-TEC obtained marketing approval for autologous cultured epidermis JACE, Japans first regenerative medical product, in October of 2007, and began marketing the product in January of 2009. J-TEC then went on to obtain marketing approval for Autologous Cultured Cartilage JACC in July of 2012, for Autologous Cultured Corneal Epithelium Nepic in March of 2020, and for Autologous Cultured Oral Mucosal Epithelium Ocural in June 2021. Of the 16 regenerative medical products that have been approved in Japan, four are J-TEC products. By making the most of the experience and knowhow cultivated through these achievements, J-TEC is engaging in contract development of regenerative medical products, consulting, and contract manufacture of specific cell-processed products.
Please visitwww.jpte.co.jp/en/
About Mitsui Fudosan Co., Ltd.
(Kashiwa-no-ha Smart City:https://www.kashiwanoha-smartcity.com/en/)
Mitsui Fudosan is a comprehensive developer that creates new value by striving to resolve social issues through urban development. At Kashiwa-no-ha Smart City, Mitsui Fudosan aims to create a smart, compact city driven by data through the introduction of new technologies such as AI and IoT. It has been selected by the Ministry of Land, Infrastructure, Transport and Tourism as an advanced model project for a smart city towards realizing Society 5.0. Going forward, Mitsui Fudosan will work on developing smart medical institution services for health and medicine. In addition, the Mitsui Fudosan Group believes that it can contribute significantly to the realization of Society 5.0, which is advocated by the Japanese government, and to the achievement of the SDGs, by promoting ESG management, which means advancing businesses based on an awareness of the Environment (E), Society (S), and Governance (G).
About National Cancer Center Japan
The National Cancer Center Japan, established in 1962, is a leading medical institution in cancer treatment and research in Japan. It is actively involved in physician-led clinical trials and clinical research, and has produced a wealth of research results that have led to the development of new drugs.
Press ContactCorporate CommunicationsTeijin Limited+81 (0)3 3506 4055pr@teijin.co.jp
Corporate Communication OfficeJapan Tissue Engineering Co., Ltd.+81 (0) 533 66 2020jtec-info@jpte.co.jp
Public Relations DepartmentMitsui Fudosan Co., Ltd.+81 (0)3 32463155
Office of Public Relations, Strategic Planning BureauNational Cancer Centerncc-admin@ncc.go.jp
- Regenerative medicine UKRI - UK Research and Innovation - December 10th, 2023
- What Is Regenerative Medicine? | Goals and Applications | ISCRM - December 2nd, 2023
- What Is Regenerative Medicine? | Mass General Brigham - December 2nd, 2023
- Advancing Safe and Effective Regenerative Medicine Products - March 20th, 2023
- Can This Companys Research Help Transform Regenerative Medicine As Its ... - December 18th, 2022
- Regenerative Medicine in Pharma Market Size, Share and Trends Analysis by Region, Drug Class, Route of Administration, and Segment Forecast, 2022-2027... - December 10th, 2022
- Stem Cells Applications in Regenerative Medicine and Disease ... - November 16th, 2022
- Neuroregeneration - Center for Regenerative Biotherapeutics - Mayo ... - November 16th, 2022
- Journal of Immunology and Regenerative Medicine - ScienceDirect - November 16th, 2022
- A Look At Some Of The Companies Innovating In the Cutting-Edge ... - November 16th, 2022
- Regenerative Medicine Advanced Therapy Designation | FDA - October 29th, 2022
- Packing More Punch for Regenerative Medicine and Cell and Gene Therapies - Inside Precision Medicine - October 29th, 2022
- Brush Up: Tissue Engineering and Regenerative Medicine - The Scientist - October 21st, 2022
- The Alliance for Regenerative Medicine Announces Election of 2023 Officers, Executive Committee, and Board of Directors - GlobeNewswire - October 13th, 2022
- Husband and Wife Team Bring Regenerative Medicine Clinic to Jackson - Franchising.com - October 13th, 2022
- Hundreds run for regenerative medicine research at the 2022 TCS London Marathon - British Heart Foundation - October 13th, 2022
- Frequency Therapeutics Completes Enrollment of Phase 2b Study of FX-322 for the Treatment of Sensorineural Hearing Loss - Yahoo Finance - October 13th, 2022
- SANUWAVE's Energy First Technology to be Featured in 3 Clinical Posters at Upcoming 2022 Fall Symposium on Advanced Wound Care (SAWC) -... - October 13th, 2022
- 3D Bioprinting Market Size to Touch Valuation of $1.5 Billion by 2028 | Inkjet Technology Generates More than 38% Revenue of Bioprinting Market -... - October 13th, 2022
- QC Kinetix (Columbia) Offers Regenerative Medicine Treatments to Treat Different Types of Physical Pain and Injuries - Yahoo Finance - October 4th, 2022
- Astellas and Pantherna Enter into a New Technology Evaluation Agreement for Research with Expanded Target Organ to Generate mRNA-Based Regenerative... - October 4th, 2022
- Company / An Advance In Vaginal Rejuvenation, Regenerative Medicine And Aesthetic Gynecology - World Nation News - October 4th, 2022
- Performance Rehabilitation and Regenerative Medicine's Dr. Joseph Mejia honored as a Castle Connolly Top Doctor - Jersey's Best - October 4th, 2022
- Cell Regeneration Medicine Market to be valued at US$ 34.3 Bn by the end of 2022 | FMI Research - PharmiWeb.com - October 4th, 2022
- Enlivex to Present at the 4th Macrophage-Directed Therapies Summit - Yahoo Finance - October 4th, 2022
- Fracturing bones and traditional views of civil engineering - ASU News Now - October 4th, 2022
- BioMarin Resubmits Biologics License Application (BLA) for Valoctocogene Roxaparvovec AAV Gene Therapy for Severe Hemophilia A to the FDA - PR... - October 4th, 2022
- Organ on a Chip Market - Focus on Products and Technologies - Distribution by Type of Product, Application Area, Purpose, and Key Geographical Regions... - October 4th, 2022
- QC Kinetix (Riverside Parkway) Offers Regenerative Medicine Treatments to Treat Pain and Injuries in Tulsa, OK - Yahoo Finance - September 25th, 2022
- Reprogramming pig cells leads way for new regenerative therapies - National Hog Farmer - September 25th, 2022
- Research Roundup: Regenerative Potential, Long COVID Insights, Immuno-Oncology and More - BioSpace - September 25th, 2022
- Dr. Batcheller's Wellness and Esthetics, Mecca for Regenerative Medicine and Esthetics - Digital Journal - September 25th, 2022
- Organicell Regenerative Medicine, Inc. Announces Expansion of Management Team - Yahoo Finance - September 25th, 2022
- Pfizer and Sangamo Therapeutics Announce Phase 3 Trial of Investigational Gene Therapy for Hemophilia A Has Re-Opened Recruitment - Pfizer - September 25th, 2022
- Neurona Therapeutics Presents Clinical Case Study from First Human Trial of Regenerative Cell Therapy, NRTX-1001, in Adults with Drug-Resistant Focal... - September 25th, 2022
- Center for Breakthrough Medicines (CBM) and jCyte Announce Strategic Partnership to Manufacture jCyte's Innovative Cell Therapy for Treatment of... - September 25th, 2022
- 2022 UK Equine Research Hall of Fame Inductees Announced The Horse - TheHorse.com - September 25th, 2022
- Science on the go: Catch the Veterinary Vertex podcast - American Veterinary Medical Association - September 25th, 2022
- Advanced robotics to address the translational gap in tendon engineering - EurekAlert - September 25th, 2022
- Russ Olsen Makes Multi-Million Dollar Pledge in support of the Robert Morris University Library - Robert Morris University - September 25th, 2022
- Humacyte Expands Board of Directors and Leadership Team with New Appointments - Yahoo Finance - September 25th, 2022
- First time in India: Stem cell therapy to treat knee osteoarthritis - Moneycontrol - September 25th, 2022
- George Church: Learn from COVID and fast-track therapies that reverse aging - Longevity.Technology - September 25th, 2022
- EpiBone CEO and Co-Founder Dr. Nina Tandon Selected to Participate in White House Summit - PR Web - September 25th, 2022
- Krystal Biotech Receives Positive Opinion from EMA Pediatric Committee on the Pediatric Investigation Plan for B-VEC for the treatment of Dystrophic... - September 25th, 2022
- Humacyte Announces Presentations by Ukrainian Surgeons on Use of the Human Acellular Vessel to Treat Wartime Vascular Trauma at the European Society... - September 25th, 2022
- Fertility Supplements And Vitamins For Women: What You Need To Know - Forbes - September 25th, 2022
- CIRM awards UCI $2.7 million to create regenerative medicine training program - UCI News - September 16th, 2022
- Regenerative Medicine Hub at W-S Innovation Quarter keeps growing with new addition - WRAL TechWire - September 16th, 2022
- QC Kinetix (Chandler): The Future of Regenerative Medicine in Arizona - Digital Journal - September 16th, 2022
- Platelet-Rich Plasma: A Promising Regenerative Therapy in Gynecological Disorders - Cureus - September 16th, 2022
- 4 to be inducted into UK Equine Research Hall of Fame - WTVQ - September 16th, 2022
- FACT SHEET: The United States Announces New Investments and Resources to Advance President Bidens National Biotechnology and Biomanufacturing... - September 16th, 2022
- AVITA Medical Achieves Positive Topline Pivotal Trial Results for Treatment of Stable Vitiligo Using the RECELL System - Yahoo Finance - September 16th, 2022
- Cell Culture Media Market worth $10.3 billion by 2026 - Exclusive Report by MarketsandMarkets - GlobeNewswire - September 16th, 2022
- Following some big FDA wins, Carmell Therapeutics plans to go public. Here's why - Technical.ly - September 16th, 2022
- Pharmaceutical Drug Delivery Market is expected to generate a revenue of USD 2,583 Billion by 2030, Globally, at 6.6% CAGR: Verified Market Research -... - September 16th, 2022
- Capstan Therapeutics Launches with $165 Million to Deliver on the Clinical Promise of Precise In Vivo Cell Engineering - Business Wire - September 16th, 2022
- Children's Health will fund pediatric unit at the Texas Health and Human Services Commission UT Southwestern Medical Center psychiatric hospital - UT... - September 16th, 2022
- Cell Line Development Market Projected to Experience a CAGR of 5% from 2022 to 2032, value worth US$ 7.66 Billion | Future Market Insights, Inc. -... - September 16th, 2022
- UB researchers identify new model of cerebral cortex development linked to reelin protein expression - EurekAlert - September 16th, 2022
- NYC Dermatologist, Dr. Julie Russak, launches first Anti-Aging Wellness Program of its kind in the U.S. - PR Web - September 16th, 2022
- About Regenerative Medicine - Center for Regenerative Biotherapeutics ... - September 8th, 2022
- Global Exosome Market Report 2022: Integration into Fields of Liquid Biopsy, Precision Medicine, and Regenerative Medicine Driving Growth -... - September 8th, 2022
- Addressing Diversity Barriers to Regenerative Medicine Free Press of Jacksonville - Jacksonville Free Press - September 8th, 2022
- Looking to buy Mesoblast shares? Here's the latest on where the ASX biotech is at with the FDA - The Motley Fool Australia - September 8th, 2022
- Sernova Announces the Appointment of Daniel Mahony, Ph.D. to its Board of Directors - GlobeNewswire - September 8th, 2022
- 7.5 Million Granted to Collaborative PROTO Project led by Charit to Study Pluri's PLX-PAD Cells for Osteoarthritis Treatment - GlobeNewswire - September 8th, 2022
- Regenerative Medicine Market to Garner Bursting Revenues [+USD 27.29 Billion] with Top Growing Companies During 2022-2029 - eTurboNews | eTN - August 30th, 2022
- ElevateBio Partners with the California Institute for Regenerative Medicine to Accelerate the Development of Regenerative Medicines - Business Wire - August 30th, 2022
- Global Cell Therapy Market to Reach a Capital Expenditure of USD 10.23 billion in 2021 - eTurboNews | eTN - August 30th, 2022
- Therapeutic Solutions International Develops Gene Silencing Therapy for Acute Respiratory Distress Syndrome - BioSpace - August 30th, 2022
- How Astrocytes May Be Able to Help With Brain Repair - Best Health Magazine - August 30th, 2022
- Applied StemCell Announces the Expansion of its cGMP Manufacturing Facility to Support Cell and Gene Therapy - Business Wire - August 30th, 2022
- Scientists just bypassed millions of years worth of evolution in mice - Inverse - August 30th, 2022
- NIAMS Update, Issue 4, 2022 | NIAMS - National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) - August 30th, 2022
- Heart Association fellowship to support research - Binghamton - August 30th, 2022
- Climate change is making the new school year harder in all kinds of ways - Salon - August 30th, 2022
- Global Biomaterials Market to Reach Value of $372.7 Billion by 2028 | Demand For Biomaterials in the Healthcare Industry will Grow by 53% Over the... - August 30th, 2022
- Dosing of Novel Autologous CAR T Cells and Nivolumab Begins in cHL Study - Targeted Oncology - August 22nd, 2022